Fastnet Rock mare Alluringly added to her already high-class stud record when True Love's victory in the Queen Mary Stakes ...

She only cost 1,000 guineas as a foal, but is a half-sister to a useful sort and a two-year-old winner, and she showed plenty to work on when runner-up over five furlongs at this course on his ...

Finn Christie’s Suffolk gimmer steals the spotlight at Angus Show, claiming back-to-back supreme titles in a fiercely competitive ring.

Reserve – J and C Fairbairn with the gelding, Cumeragh House Pioneer. Gelding, mare – J and C Fairbairn. Yearling/two-year-old colt or gelding, yearling/two-year-old filly – Mrs J Butterworth. Mare ...

Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other ...

Actress Evangeline Lilly shared her hospital experience after fainting on a beach, revealing injuries and a long history of unexplained blackouts.

Investing.com -- Eli Lilly and Company (NYSE:LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a deal worth up to $1 billion, deepening its bet on non ...

Eli Lilly is expanding its efforts to advance next-generation pain medications. The Big Pharma has penned a deal to acquire SiteOne Therapeutics, primarily for a non-opioid pain asset ready to ...

Lilly will lead STC-004 through phase 2 trials and commercialisation for global markets. In return, SiteOne and its shareholders could receive up to $1bn […] Global biopharma Eli Lilly will acquire ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain medicine.

Eli Lilly increased its revenue from $8,768 million in Q1 2024 to $12,728.5 million in Q1 2025 – resulting in 45.2% year-over-year growth for the top line.